The AMR Narrative

Inappropriate use of antibiotics and C. diff: what is the connection?

Antimicrobial resistance (AMR) is a natural phenomenon occurring when microorganisms – such as viruses, bacteria, fungi, and parasites – become resistant to the antimicrobial medicines designed to fight them. In other words, these medicines become less and less effective or totally ineffective in treating the infections caused by these resistant microorganisms. That’s why AMR is considered a growing public health issue.

As we know, the misuse and overuse of antimicrobials in humans, animals and plants are among the major contributors to the development of AMR in microorganisms. For instance, let’s consider antibiotics, medicines used to treat infections caused by bacteria. The inappropriate use of antibiotics may contribute to the development of resistant bacteria and their spread in patients within and across hospitals, countries, and globally.

But there is more. Do you know that the incorrect use of antibiotics can raise the risk of Clostridioides difficile infection? Have you ever heard about that?

Its name sounds like a tongue-twister, but this microorganism is not at all friendly, believe me. As a matter of fact, Clostridioides difficile (also named C. diff) is the most common cause of diarrhoea in hospitalised patients and is one of the most important microorganisms related to healthcare-associated infections.

Please, let me introduce you to this bug.

C. diff
is a rod-shaped bacterium that is rarely found in the intestine of healthy adults. It has got the ability to form spores by surrounding itself with a very strong structure. It is this sort of a “shell” that enables C. diff to survive in harsh environmental conditions.

It is transmitted through the faecal-oral route. For example, in healthcare facilities C. diff can be acquired through the ingestion of spores contaminating the hands of other patients or healthcare workers, or from environmental surfaces. These swallowed spores survive the acid environment of the stomach, and then germinate in the intestine (in plain words, it means that C. diff bacteria come out of their “shells” and become active). Here, they can produce toxins (called toxin A and toxin B), which are responsible for the clinical manifestations of the infection.

Symptoms and signs may vary, from diarrhoea to fulminant sepsis with toxic megacolon, a severe condition characterised by high mortality.

There are several risk factors for C. diff infection.

The use – and clearly misuse and overuse, as well – of antibiotics is one of the risk factors. Indeed, as observed by several studies, the risk of C. diff infection increases when the duration of the antibiotic therapy exceeds 10 days. Moreover, the risk of infection increases up to 6 times during and in the month following antibiotic therapy. Nearly all antibiotics have been associated with C. diff infection; however, clindamycin, penicillins, third-generation cephalosporins and fluoroquinolones pose the greatest risk.

Now, you might be wondering: how does it happen? And why?

In our intestine both “good” and “bad” bacteria live together in a balance for protecting our body from infections and maintaining health. In normal conditions, “good” bacteria help to keep other bacteria, such as C. diff, in check. The use of antibiotics inevitably changes the normal intestinal flora by upsetting this delicate balance between microorganisms. This alteration may create favourable conditions for the proliferation of C. diff bacteria which finally can start producing bad toxins responsible for infection. That’s the problem.

In order to prevent and stop C. diff some basic measures must be promptly implemented.

Hand hygiene with soap and water is the golden rule. Indeed, the transmission of spores occurs mainly through contaminated hands. This is the cornerstone of prevention and control of all healthcare-associated infections, and especially for C. diff infection. Indeed, alcohol-based hand disinfectants are not effective against C. diff spores.

Moreover, in healthcare facilities patients with established (or even suspected) C. diff infection must undergo contact isolation precautions promptly. These measures must be followed by visitors and healthcare workers before entering and after leaving the patient’s room in order to prevent spores from spreading, thus reducing transmission between patients and environmental contamination.

Then, do not forget adequate environmental disinfection. Preventing C. diff infection in hospitals is a challenge because spores can survive on surfaces for months, and thorough cleaning and disinfection are necessary to remove them from the environment (for example, on the bed, floor, sink and light switches). Disinfection with sodium hypochlorite solutions is generally recommended in areas of healthcare facilities contaminated with C. diff.

The last but not the least, the appropriate use of antibiotics play an essential role in preventing C. diff infection, for the reasons we mentioned earlier.

In conclusion, we have learnt that the judicious use of antibiotics is crucial not only to counteract the emergence and spread of bacterial AMR.

Using these essential and life-saving medicines responsibly is also essential to reduce the risk of C. diff infection. Only take antibiotics when prescribed for you by your doctor, and always follow your doctor’s advice and instructions when taking antibiotics. Don’t forget it.

Francesco M. Labricciosa

Francesco M. Labricciosa is a Medical Doctor from Italy. After earning a post-graduate diploma in Primary Care Medicine, he consolidated his experience in different healthcare settings, and then became a specialist in Hygiene and Preventive Medicine.

Antimicrobial Resistance (AMR), optimal and prudent use of antimicrobials, and awareness towards consumption of these medications represent his main fields of interest.

Since 2016, he has been working with the Global Alliance for Infections in Surgery. He participated in several international research projects about prevention and management of healthcare-associated infections, surgical antibiotic prophylaxis, antimicrobial therapy in intra-abdominal infections, and antimicrobial stewardship programs. He has co-authored more than 40 articles published in peer-reviewed medical journals.

In 2023 he started an interesting collaboration with The AMR Narrative, serving as an Independent Advisor for the charity, and writing blogs to promote public understanding and education for AMR.

Moreover, Francesco works with several medical communication agencies in designing and finalising educational materials aimed at diversified audiences. Finally, he takes an active role in science communication blogging about antimicrobial use and AMR.

Supplementary Scientific Information:

Clostridioides difficile (C. difficile) is a key pathogen that disrupts gut homeostasis, particularly in healthcare settings. Its relationship with the gut microbiome is complex and plays a crucial role in both infection pathogenesis and recovery. Here’s an overview of key aspects:

Gut Microbiome and Colonisation Resistance

A healthy gut microbiome provides colonisation resistance against
C. difficile by maintaining microbial diversity and metabolic functions.

  • Commensal bacteria, such as Bacteroidetes and Firmicutes, produce short-chain fatty
    acids (SCFAs) (e.g., butyrate) that regulate intestinal barrier function and immune responses.
  • Competition for nutrients and adhesion sites limits C. difficile growth in a balanced microbiome.

Disruption of the Microbiome and C. difficile Overgrowth

  • Antibiotic Use: Broad-spectrum antibiotics (e.g., clindamycin, cephalosporins, fluoroquinolones) deplete beneficial gut bacteria, reducing colonisation resistance and allowing C. difficile spores to germinate.
  • Dysbiosis: Reduction in key microbial groups (e.g., Firmicutes and Bacteroidetes) leads to increased availability of primary bile acids that promote C. difficile spore germination.
  • Inflammation & Immune Dysregulation: Dysbiosis alters mucosal immunity, allowing C. difficile toxins (TcdA and TcdB) to damage intestinal epithelial cells.



    C. difficile
    Infection (CDI) and Microbiome Disruptions

  • Recurrent CDI (rCDI): Microbiome dysfunction predisposes individuals to recurrent infections, often requiring faecal microbiota transplantation (FMT) for restoration.
  • Metabolic Shifts: C. difficile thrives in a disrupted microbiome by fermenting simple sugars and utilising amino acids from host epithelial damage.

Microbiome-Based Interventions

  • FMT: Restores microbial diversity, reducing C. difficile recurrence rates.
  • Probiotics: Lactobacillus and Saccharomyces boulardii may help prevent CDI, though efficacy is variable.
  • Next-Generation Microbiota Therapies: Live biotherapeutics (e.g., SER-109) derived from purified microbiota compositions aim to prevent CDI recurrence.
  • Prebiotics & Diet: Fibre-rich diets promote SCFA production, supporting microbiome resilience against C. difficile.

Future Directions

  • Microbiome Engineering: Synthetic microbial consortia to outcompete C. difficile.
  • Metabolite-Based Therapies: Targeting bile acid metabolism to suppress C. difficile growth.
  • Host-Immune Modulation: Strategies to strengthen mucosal immunity alongside microbiome restoration.

The gut microbiome plays a pivotal role in preventing and managing C. difficile infections, highlighting the importance of microbiome preservation in antimicrobial stewardship programmes.

Dr Marie-Anne Bouldouyre

Dr Marie-Anne Bouldouyre is an infectious diseases physician and hospital practitioner in Paris. Twelve years of clinical work in a suburban hospital shaped her understanding of access to care, patient relationships, and the daily reality of antimicrobial resistance.

Since 2022, she has led the Regional Antibiotic Stewardship Centre in Île-de-France and coordinates the national network, working with a multidisciplinary team to promote responsible antibiotic use and strengthen collaboration among healthcare professionals. She also continues to manage complex infections at Saint-Louis Hospital.

Convinced that antimicrobial resistance cannot be tackled by healthcare workers alone, she advocates for the active involvement of patients : understanding, questioning, and taking part in decisions about antibiotics. Their stories are essential to making this issue visible and concrete.

She is proud to collaborate with initiatives such as The AMR Narrative and hopes to foster similar projects in France to give patients a voice in this shared fight.

Dr Erva Cinar

Dr Erva Cinar is a London based paediatric resident doctor and clinical researcher with interest in infectious diseases.

She is currently completing a Master’s in Public Health at the London School of Hygiene & Tropical Medicine. Through the World Medical Association’s Junior Doctor’s Network (WMA-JDN) AMR Working Group, she engages in policy and advocacy on antimicrobial resistance and stewardship at global level.

Alongside her clinical and academic roles, she works with the Royal College of Paediatrics and Child Health (RCPCH) and the International Child Health Group (ICHG); leads on organising teaching resources and educational events to improve research skills for UK paediatric trainees and for global child health professionals.

Hamu Madzedze

Hamu Madzedze is a seasoned Zimbabwean journalist with over 15 years’ experience.

She previously worked for the Zimbabwe Broadcasting Corporation as a reporter and sub-editor, before establishing an independent website, 365HealthDiaries, which focuses on health and gender issues.

She holds a BA in Media Studies and a BA (Special Honours) in Communication and Media from the Zimbabwe Open University, as well as a diploma from the Christian College of Southern Africa.

Her work has been recognised with several awards, including the Global AMR Special Mention Award (2024), the Sexual Health Rights and Equity Fellowship Special Mention Award (2025), and the Merck Foundation Award (2024) for outstanding coverage of health issues, gender, infertility, and genital mutilation, where she achieved third position in the Online Category.

Hamu is passionate about addressing AMR through the media.

Jomana F. Musmar

Dr. Jomana Musmar is a distinguished global policy expert and proactive leader with over fifteen years of government experience in strategic planning, operational design, and policy execution. Renowned for simplifying complex topics with expertise and diplomacy, she has spearheaded innovative solutions to global health challenges, shaped impactful policies, and advanced national and international missions.

As the Executive Director of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, she established and led the council’s operations, liaising with over 600 experts, worldwide, across government, industry, and academia. Her efforts culminated in the development of critical recommendations addressing antimicrobial resistance and interrelated One Health issues, influencing both domestic and global health strategies.

In her tenure as Deputy Director of Strategic Initiatives for the Office of Infectious Diseases and HIV/AIDS Policy, at the US Department of Health and Human Services, Dr. Musmar oversaw the formulation and implementation of national health strategies for vaccines and a range of infectious diseases including HIV/AIDS and viral hepatitis. Her leadership and technical expertise facilitated groundbreaking policies during national emergencies, including responses to the COVID-19 pandemic, and initiatives to combat congenital syphilis and childhood vaccination disruptions. Dr. Musmar holds a Ph.D. in Biodefense from George Mason University, a Master’s degree in Biomedical Science policy and Advocacy from Georgetown University, and is a Lean Six Sigma Black Belt. Fluent in English and Arabic, she is a sought-after speaker and advisor, having represented the United States at premier global health conferences.

Her published works on antimicrobial resistance, pandemic preparedness, and national health security underscore her reputation as a thought leader and innovator in public health and biodefense.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.